Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD3293 Formulations in Healthy Volunteers
NCT02039180Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Relative bioavailability of AZD3293 (AUC0-inf) at Day 18 and Basic pharmacokinetic parameters at Day 18. Started Feb 2014; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02039180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039180.